Literature DB >> 16963034

The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects.

Richard S Legro1, Evan R Myers, Huiman X Barnhart, Sandra A Carson, Michael P Diamond, Bruce R Carr, William D Schlaff, Christos Coutifaris, Peter G McGovern, Nicholas A Cataldo, Michael P Steinkampf, John E Nestler, Gabriella Gosman, Linda C Guidice, Phyllis C Leppert.   

Abstract

OBJECTIVE: To report the baseline characteristics and racial differences in the polycystic ovary syndrome (PCOS) phenotype from a large multicenter clinical trial (PPCOS).
DESIGN: Double-blind, randomized trial of three treatment regimens (with extended release metformin or clomiphene citrate).
SETTING: Academic medical centers. PATIENT(S): Six hundred twenty-six infertile women with PCOS, aged 18-39 years, with elevated T levels and oligomenorrhea (exclusion of secondary causes), seeking pregnancy, with > or = 1 patent fallopian tube, normal uterine cavity, and a partner with sperm concentration > or = 20 x 10(6)/mL in > or = 1 ejaculate. INTERVENTION(S): Baseline characterization. MAIN OUTCOME MEASURE(S): Historical, biometric, and biochemical measures of PCOS. RESULT(S): There were no significant differences in baseline variables between treatment groups. The overall mean (+/-SD) age of the subjects was 28.1 +/- 4.0 years, and the mean body mass index was 35.2 kg/m2 (+/-8.7). Polycystic ovaries (PCOs) were present in 90.3% of the subjects, and the mean volume of each ovary was 10 cm3 or more. Of the subjects, 7% had ovaries that were discordant for PCO morphology. At baseline, 18.3% of the subjects had an abnormal fasting glucose level (> 100 mg/dL). Asians tended to have a milder phenotype, and whites and African Americans were similar in these measures. CONCLUSION(S): The treatment groups were well matched for baseline parameters, and we have added further information to the PCOS phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963034     DOI: 10.1016/j.fertnstert.2006.03.037

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  39 in total

1.  Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.

Authors:  Mira Aubuchon; Allen R Kunselman; William D Schlaff; Michael P Diamond; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

Review 2.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

3.  Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study.

Authors:  Gwinnett Ladson; William C Dodson; Stephanie D Sweet; Anthony E Archibong; Allen R Kunselman; Laurence M Demers; Nancy I Williams; Ponjola Coney; Richard S Legro
Journal:  Fertil Steril       Date:  2011-07       Impact factor: 7.329

4.  Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility.

Authors:  Hao Huang; Hongying Kuang; Fangbai Sun; Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter R Casson; Gregory M Christman; Karl R Hansen; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2019-03-27       Impact factor: 7.329

5.  Impact of Male and Female Weight, Smoking, and Intercourse Frequency on Live Birth in Women With Polycystic Ovary Syndrome.

Authors:  Alex J Polotsky; Amanda A Allshouse; Peter R Casson; Christos Coutifaris; Michael P Diamond; Gregory M Christman; William D Schlaff; Ruben Alvero; J C Trussell; Stephen A Krawetz; Nanette Santoro; Esther Eisenberg; Heping Zhang; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2015-04-09       Impact factor: 5.958

6.  Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.

Authors:  Mark O Goodarzi; Michelle R Jones; Xiaohui Li; Angela K Chua; Obed A Garcia; Yii-Der I Chen; Ronald M Krauss; Jerome I Rotter; Wendy Ankener; Richard S Legro; Ricardo Azziz; Jerome F Strauss; Andrea Dunaif; Margrit Urbanek
Journal:  J Med Genet       Date:  2011-12-17       Impact factor: 6.318

7.  Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.

Authors:  Lauren W Roth; Hao Huang; Richard S Legro; Michael P Diamond; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Heping Zhang; William D Schlaff
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

Review 8.  [Cutaneous manifestations of metabolic syndrome].

Authors:  G Holzer; B Straßegger; B Volc-Platzer
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

9.  Impact of obesity on the risk for polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Eric S Knochenhauer; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

10.  Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.

Authors:  Richard S Legro; Huiman X Barnhart; William D Schlaff; Bruce R Carr; Michael P Diamond; Sandra A Carson; Michael P Steinkampf; Christos Coutifaris; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Linda C Giudice; Kathryn G Ewens; Richard S Spielman; Phyllis C Leppert; Evan R Myers
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.